Cobo Marc received 9,038 BridgeBio Oncology Therapeutics shares and 43,700 derivative securities, while forfeiting 203 shares at $5.52 each on September 10, 2026. The transaction record separates common-stock awards, a share forfeiture and derivative securities, allowing investors to assess Cobo Marc’s resulting holdings across each instrument type.
Key Highlights
- Cobo Marc’s 9,038-share award left the principal accounting officer with 14,344 shares.
- A separate award added 43,700 derivative securities to Cobo Marc’s holdings.
- The 203-share forfeiture represented about 1.4% of Cobo Marc’s prior share holding.
The filing reported an award of shares, a share forfeiture, and an award of derivative securities.
BridgeBio Awards Add Shares and Derivative Securities
After that award, Cobo Marc held 14,344 shares. The transaction carried code A. A separate code A transaction awarded Cobo Marc 43,700 derivative securities. The 203-share transaction carried code F.
Post-Transaction Holdings
The 9,038-share award represented about 63.0% of Cobo Marc’s resulting share holding. The 203-share forfeiture represented about 1.4% of the prior share holding, leaving Cobo Marc with 14,141 shares after the transaction. The derivative securities award represented about 100.0% of Cobo Marc’s resulting derivative securities holding. The filing reports these percentages for the respective share and derivative-security holdings.
FAQs
Q: What did Cobo Marc receive from BridgeBio Oncology Therapeutics?
A: Cobo Marc was awarded 9,038 shares and 43,700 derivative securities of BridgeBio Oncology Therapeutics on September 10, 2026. The share award carried SEC transaction code A.
Q: How many BridgeBio shares did Cobo Marc forfeit?
A: Cobo Marc forfeited 203 BridgeBio Oncology Therapeutics shares at $5.52 per share on September 10, 2026, in a transaction carrying SEC code F. After the transaction, Cobo Marc held 14,141 shares.
Q: What was Cobo Marc’s resulting derivative securities holding?
A: Cobo Marc held 43,700 derivative securities after the award. The transaction represented about 100.0% of the resulting derivative securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.